- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Fezakinumab is a fully human monoclonal anti-IL22 antibody being investigated for clinical antiinflammatory utility against acute and chronic conditions.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequences identical to those of the heavy and light variable regions of fezakinumab are claimed in patent US7811567, leading to identification of clone 356A11 as fezakinumab .
1. Fouser LA, Hegen M, Luxenberg DP, O'Toole M. (2010)
Methods of using antibodies against human IL-22.
Patent number: US7811567. Assignee: Wyeth Llc. Priority date: 21/02/2006. Publication date: 12/10/2010.